Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7) represents a potential target for CAR T-cell therapy in the treatment of multiple myeloma (MM), and it is a promising alternative to classic BCMA-CAR therapy. The receptor is expressed on immune cells, particularly natural killer cells and T cells, that can trigger both activating and inhibitory signals. It is highly expressed in MM cells at all disease stages, playing a crucial role in cell adhesion and communication between immune cells, and being involved in the development and progression of the disease. The target has a proven clinical success with Elotuzumab (anti-SLAMF7 antibody); it works by activating immune cells to kill myeloma cells, and limited expression on normal tissues, with, potentially, few side effects. SLAMF7’s combination of specificity, stability, and clinical validation makes it an excellent target for current and future MM therapies. However, ‘fratricide death’, a phenomenon where the engineered CAR-T cells attack and kill each other, is a critical issue that requires safe engineering solutions. In this work, we will provide an overview on the field with a specific focus on SLAMF7 as an emerging CAR-T cell target in MM.
信号淋巴细胞激活分子家族成员7（SLAMF7）是治疗多发性骨髓瘤（MM）的CAR T细胞疗法的一个潜在靶点，也是经典BCMA-CAR疗法的一种有前景的替代方案。该受体在免疫细胞上表达，特别是自然杀伤细胞和T细胞，能够触发激活和抑制信号。它在所有疾病阶段的MM细胞中高度表达，在细胞粘附和免疫细胞间的通讯中发挥关键作用，并参与疾病的发生和发展。该靶点已在Elotuzumab（抗SLAMF7抗体）中取得临床成功；其作用机制是通过激活免疫细胞来杀死骨髓瘤细胞，且在正常组织中的表达有限，副作用可能较少。SLAMF7的特异性、稳定性和临床验证相结合，使其成为当前和未来MM治疗的优秀靶点。然而，“自相残杀”现象——即工程化的CAR-T细胞相互攻击和杀死——是一个关键问题，需要安全的工程解决方案。在这项工作中，我们将对该领域进行概述，特别关注SLAMF7作为MM中新兴的CAR-T细胞靶点。
SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma
肿瘤(癌症)患者之家